COVID-19

Covid-19; Long Term Heart Damage? Short Duration of Immunity? Ed Mistarka

Covid-19 is not behaving like we assumed it would. Much of the evidence suggests it will not just go away after we just have mild symptoms, like a cold or a flu, and that the duration of immunity is not as long as we were hoping it would be. Numerous recent peer reviewed publications are cited in this video.

“This means that the heart is involved in a majority of patients, even if Covid-19 illness does not scream out with the classical heart symptoms, such as anginal chest pain,” Valentina Puntmann, who led the study, told STAT. “The relatively clear onset of Covid-19 illness provides an opportunity to take proactive action.”

“Clyde Yancy, a cardiologist at Northwestern’s Feinberg School of Medicine, and Gregg Fonarow, a cardiologist at UCLA’s Geffen School of Medicine, wrote an editorial about the two recent studies on heart problems related to the novel coronavirus and called for more research into the problem.

“If this high rate of risk is confirmed, … then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications,” they wrote. “We are inclined to raise a new and very evident concern that cardiomyopathy and heart failure related to Covid-19 may potentially evolve as the natural history of this infection becomes clearer.””

This publication was reviewed after the video was filmed:
“Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?
Clyde W. Yancy, MD, MSc1,2; Gregg C. Fonarow, MD3,4
Author Affiliations Article Information
JAMA Cardiol. Published online July 27, 2020. doi:10.1001/jamacardio.2020.3575 ”

“Yet, if this high rate of risk is confirmed, the pathologic basis for progressive left ventricular dysfunction is validated, and especially if longitudinal assessment reveals new-onset heart failure in the recovery phase of COVID-19, then the crisis of COVID-19 will not abate but will instead shift to a new de novo incidence of heart failure and other chronic cardiovascular complications.”